Expression of tumor necrosis factor–related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis
Authors:
Open Access
- 15 November 2001
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 98 (10) , 3058-3065
Abstract
Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor (TNF) family, binds to several cell-surface receptors with distinct functions (agonistic receptors 1 and 2 [TRAIL-R1, TRAIL-R2]; decoy receptors 3 and 4 [TRAIL-R3, TRAIL-R4]). Expression and function was characterized in patients with myelodysplastic syndromes (MDSs). While normal marrow showed negligible expression of TRAIL and receptors (except TRAIL-R3), TRAIL and all receptors were constitutively expressed in MDS marrow. Following TRAIL exposure, MDS marrow showed significant increases in apoptosis, whereas normal marrow, except for a subset of CD34+ precursors, did not (P = .012). Marrow from 21 patients with MDS was then propagated in long-term cultures in the presence or absence of TRAIL. While in advanced MDS (refractory anemia with excess blasts in transformation [RAEB-T] and tAML [MDS transformed into AML]), colony numbers decreased in the presence of TRAIL (63.0% ± 10.4% of untreated group [100%]), numbers increased in patients with RA or RAEB (160.2% ± 90.5% of untreated group). TRAIL eliminated preferentially clonally abnormal cells as identified by chromosomal markers. Thus, TRAIL and receptor expression differed significantly between normal and MDS marrow, and TRAIL modulated in vitro hemopoiesis in MDS dependent upon disease stage but not, to a detectable extent, in normal marrow.Keywords
This publication has 32 references indexed in Scilit:
- FADD Is Required for DR4- and DR5-mediated ApoptosisJournal of Biological Chemistry, 2000
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- MyelodysplasiaNew England Journal of Medicine, 1999
- Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemiaLeukemia, 1998
- Ineffective haemopoiesis and apoptosis in myelodysplastic syndromesBritish Journal of Haematology, 1998
- Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromesLeukemia Research, 1996
- Prediction of Relapse of Pediatric Acute Myeloid Leukemia by Use of Multidimensional Flow CytometryJNCI: Journal of the National Cancer Institute, 1996
- CD45 Gating for Routine Flow Cytometric Analysis of Human Bone Marrow SpecimensAnnals of the New York Academy of Sciences, 1993
- The Role of GM-CSF, G-CSF, Interleukin-3, and Erythropoietin in Myelodysplastic SyndromesAmerican Journal of Clinical Oncology, 1991
- Conditions controlling the proliferation of haemopoietic stem cells in vitroJournal of Cellular Physiology, 1977